Showing items 1 - 20 of 37

Your selections:

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

Interconnections between unintended pregnancy, alcohol and other drug use, and pregnancy, birth, infant, childhood and socioeconomic outcomes: a scoping review

Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention

Understanding the research capacity of alcohol and other drugs services in New South Wales, Australia

Health and Social Characteristics of Clients Reporting Amphetamine Type Substance Use at Entry to Public Alcohol and Other Drug Services in New South Wales, Australia, 2016–2019

Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder

Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions

Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial

Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial

Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

Assessing the concurrent validity, inter-rater reliability and test-re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations

Patient-Reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings

Acute experimental pain responses in methadone- and buprenorphine/naloxone-maintained patients administered additional opioid or gabapentin: a double-blind crossover pilot study

Assessing the validity of the Australian treatment outcomes profile for telephone administration in drug health treatment populations

Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial

  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit